Clinical trial · Interventional
Edwards EVOQUE Eos MISCEND Study
Edwards EVOQUE Eos Mitral Valve Replacement: Investigation of Safety and Performance After Mitral Valve Replacement With Transcatheter Device (MISCEND)
NCT02718001CI-TRIAL-00108010active not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Study to evaluate the safety and performance of the Edwards EVOQUE Eos mitral valve replacement system
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Mitral Valve Regurgitation (Degenerative or Functional) | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Edwards EVOQUE Eos Mitral Valve Replacement System | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment
- description
- Treatment with the Edwards EVOQUE Eos mitral valve replacement system
- interventionNames
- Device: Edwards EVOQUE Eos Mitral Valve Replacement System
Primary outcomes (1)
- measure
- Composite of major adverse events
- timeFrame
- 30 days
- description
- Proportion of patients with major adverse events
Secondary outcomes (6)
- measure
- NYHA functional class
- timeFrame
- 30 days, 6 Months, 12 Months, annual for five years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Clinically significant, symptomatic mitral regurgitation * High risk for open-heart surgery * Meets anatomical criteria Exclusion Criteria: * Unsuitable anatomy * Patient is inoperable
References
Publications (0)
Data not yet available
No reference posted for this study.